Mannitol + TobramycinContraindicated
Intravenous mannitol not recommended due to possible enhancement of aminoglycoside toxicity by altering serum and tissue concentrations.
Source: NLP:tobramycin
Mannitol Interactions
Brand names: Mannitol
Osmotic Diuretic · Osmotic Activity
Route: Intravenous
FDA Black Box Warning
WARNING: RISK OF SEVERE BRONCHOSPASM Mannitol, the active ingredient in ARIDOL, acts as a bronchoconstrictor and may cause severe bronchospasm. Bronchial challenge testing with ARIDOL is for diagnostic purposes only. Bronchial challenge testing with ARIDOL should only be conducted by trained professionals under the supervision of a physician familiar with all aspects of the bronchial challenge test and the management of acute bronchospasm. Medications (such as short-acting inhaled beta-agonist) and equipment to treat severe bronchospasm must be present in the testing area. If severe bronchospasm occurs it should be treated immediately by administration of a short-acting inhaled beta-agonist. Because of the potential for severe bronchoconstriction, the bronchial challenge testing with ARIDOL should not be performed in any patient with clinically apparent asthma or very low baseline pulmonary function tests (e.g., FEV 1 <1-1.5 liters or <70% of the predicted values) [ see Warnings and Precautions ( 5.1 ) ]. WARNING: RISK OF SEVERE BRONCHOSPASM See full prescribing information for complete boxed warning. Mannitol, the active ingredient in ARIDOL, acts as a bronchoconstrictor and may cause severe bronchospasm. Bronchial challenge testing with ARIDOL is for diagnostic purposes only. Only trained professionals under the supervision of a physician who are familiar with the management of acute bronchospasm should perform bronchial challenge testing with ARIDOL. Medications (such as short-acting inhaled beta-agonist) and equipment to treat severe bronchospasm must be present in the testing area. Because of the potential for severe bronchoconstriction, bronchial challenge testing with ARIDOL should not be performed in any patient with clinically apparent asthma or very low baseline pulmonary function tests (e.g., FEV 1 <1-1.5 liters or <70% of the predicted values) ( 5.1 )
Contraindications
4 CONTRAINDICATIONS Mannitol Injection is contraindicated in patients with: Hypersensitivity to mannitol [see Warnings and Precautions (5.1)] Anuria [see Warnings and Precautions (5.2)] Severe hypovolemia [see Warnings and Precautions (5.4)] Pre-existing severe pulmonary vascular congestion or pulmonary edema [see Warnings and Precautions (5.5)] Active intracranial bleeding except during craniotomy. Known hypersensitivity to mannitol. ( 4 , 5.1 ) Anuria. ( 4 , 5.2 ) Severe hypovolemia. ( 4 , 5.4 ) Pre-existing severe pulmonary vascular congestion or pulmonary edema. ( 4 , 5.5 ) Active intracranial bleeding except during craniotomy. ( 4 )
Pregnancy & Breastfeeding
8.1 Pregnancy Risk Summary The available case report data with mannitol over decades of use have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Mannitol crosses the placenta and may cause fluid shifts that could potentially result in adverse effects in the fetus (see Data) . No adverse developmental effects from mannitol were reported in published animal studies; however, fluid shifts occurred in fetal ewes in response to maternal infusion of mannitol. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Human Data Published literature reports the presence of mannitol in amniotic fluid when mannitol is administered to pregnant women during the third trimester of pregnancy.
10 interactions on record
Electrolyte imbalances caused by mannitol may result in cardiac adverse reactions. Monitor serum electrolytes and discontinue if cardiac status worsens.
Source: NLP:mannitol
Mannitol + AmikacinMajor
Intravenous mannitol can enhance aminoglycoside toxicity by altering serum and tissue concentrations. Avoid concomitant use.
Source: NLP:amikacin
Nephrotoxic drug that increases risk of renal failure when used concomitantly with mannitol; avoid use if possible.
Source: NLP:mannitol
Mannitol + DigoxinMajor
Electrolyte imbalances caused by mannitol may result in cardiac adverse reactions in patients receiving digoxin. Monitor serum electrolytes and discontinue if cardiac status worsens.
Source: NLP:mannitol
Mannitol + DiureticsMajor
Concomitant administration may potentiate the renal toxicity of mannitol; avoid use if possible.
Source: NLP:mannitol
Mannitol + LithiumMajor
Concomitant use may increase risk of lithium toxicity, especially if hypovolemia or renal impairment develops; frequently monitor lithium concentrations and signs of toxicity.
Source: NLP:mannitol
Concomitant administration can enhance aminoglycoside toxicity by altering aminoglycoside concentrations in serum and tissue.
Source: NLP:tobramycin solution
Electrolyte imbalances from mannitol may result in cardiac adverse reactions; monitor serum electrolytes.
Source: NLP:mannitol
Compounds that quench active oxygen species or scavenge radicals would be expected to decrease VISUDYNE activity.
Source: NLP:verteporfin for injection